Pfizer
Drug Manufacturers - General · PFIZER
Mid CapHealthcareMature Stable
Meenakshi Nevatia
Managing Director · Visionary
Company DNA
Hierarchical
About
Pfizer is a Mid Cap company in the Healthcare sector, listed on NSE as PFIZER. With a market cap of ₹22K Cr and revenue of ₹2K Cr, it is currently in the Mature Stable phase. Known for its Hierarchical culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Follows a structured global corporate hierarchy and professional management protocols inherent in a large, stable, MNC-subsidiary pharmaceutical environment. Its strategic mandate: The company must pivot its portfolio toward high-growth therapeutic segments to counter the maturity of legacy product lines.
FAQ
What kind of company is Pfizer?
Pfizer is a Mid Cap Healthcare company (PFIZER) in the Mature Stable phase with a market cap of ₹22K Cr. It is classified as Hierarchical in culture.
What is Pfizer's culture and work environment like?
Pfizer has a Hierarchical culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2G-Institutional. Follows a structured global corporate hierarchy and professional management protocols inherent in a large, stable, MNC-subsidiary pharmaceutical environment.
Who leads Pfizer?
Pfizer is led by Meenakshi Nevatia (Managing Director), a Visionary leader with 31 years of experience.
What are Pfizer's financials?
Pfizer reported revenue of ₹2K Cr in FY25 with a 5-year revenue CAGR of -4.4%. Operating margin: 29.9%. Market cap: ₹22K Cr.
Culture & Strategy
CultureHierarchical
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2G-Institutional
EmployeeSteady Employer
BrandTrusted
LifecycleMature Stable
Follows a structured global corporate hierarchy and professional management protocols inherent in a large, stable, MNC-subsidiary pharmaceutical environment.
Mandate
The company must pivot its portfolio toward high-growth therapeutic segments to counter the maturity of legacy product lines.
The company must pivot its portfolio toward high-growth therapeutic segments to counter the maturity of legacy product lines.
Financials
Revenue FY25₹2K Cr
PAT FY25₹768 Cr
Rev CAGR 5Y-4.4%
OPM29.9%
NPM33.7%
ROE18.2%
ROCE15.7%
P/E24.8
Fwd P/E24.4
P/B5.5
D/E2.3
Mkt Cap₹22K Cr
Promoter67%
Institutional18%
Similar Culture
Could You Lead Pfizer?
Take the Genome Benchmark →